Holen Sie sich die Stockscreener-App
1.31
6.50%
0.08
Handel nachbörslich:
1.30
-0.01
-0.76%
Schlusskurs vom Vortag:
$1.23
Offen:
$1.22
24-Stunden-Volumen:
8.06M
Relative Volume:
0.87
Marktkapitalisierung:
$393.49M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-0.8733
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-2.96%
1M Leistung:
-9.03%
6M Leistung:
-29.19%
1J Leistung:
-22.49%
1-Tages-Spanne:
$1.21
$1.35
1-Wochen-Bereich:
$1.185
$1.3767
52-Wochen-Spanne:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Vergleichen Sie PACB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.31 | 369.46M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
What’s the profit margin of Pacific Biosciences of California Inc.Gap Down & Expert Verified Movement Alerts - newsyoung.net
Will Pacific Biosciences of California Inc. benefit from seasonalityJuly 2025 Retail & Consistent Profit Focused Trading Strategies - sundaytimes.kr
Pacific Biosciences Of California, Inc. shares fall 1.53% after-hours following Zentek Ltd.'s MD&A release. - AInvest
Published on: 2025-08-15 04:22:23 - thegnnews.com
PacBio (PACB) Shares Skyrocket, What You Need To Know - TradingView
PacBio’s Path: Upward Surge or Shortlived Spike? - StocksToTrade
Pacific Biosciences Of California, Inc. shares rise 1.65% premarket. - AInvest
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q2 2025 Earnings Call Transcript - Insider Monkey
The Analyst Verdict: Pacific Biosciences In The Eyes Of 4 Experts - 富途牛牛
PACB Q2 Deep Dive: International Demand, Consumables Growth, and Clinical Adoption Drive Results - FinancialContent
PACB Analyst Update: Piper Sandler Raises Price Target by 20% | - GuruFocus
Pacific Biosciences: Piper Sandler Keeps Neutral Rating, Raises PT to $1.5 - AInvest
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - 富途牛牛
Pacific Biosciences of California Earnings: Analysts Boost Forecasts for 2025 - AInvest
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - uk.finance.yahoo.com
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - msn.com
Pacific Biosciences Q2 2025 Revenue Surpasses Analyst Estimate at $39.8 Million, GAAP Net Loss Narrows to $0.14 - AInvest
PacBio Reports Q2 EPS, Revenue Growth, and Positive Cash Flow - AInvest
Pacific Biosciences Receives Buy Rating from Bernstein, Maintains $1.70 Price Target - AInvest
Pacific Biosciences shares rise 3.57% intraday after reporting smaller-than-expected Q2 loss and positive trial data. - AInvest
PacBio (PACB) Stock Trades Up, Here Is Why - Yahoo Finance
Bernstein Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $1.7 - 富途牛牛
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises - Yahoo Finance
Pacific Biosciences stock price target raised by Bernstein to $1.70 on clinical uptake - Investing.com Canada
Powered by PacBio: Selected publications from July 2025 - PacBio
Earnings call transcript: Pacific Biosciences Q2 2025 beats revenue expectations, stock surges - Investing.com Canada
Pacific Biosciences: Q2 Earnings Snapshot - Connecticut Post
Pacific Biosciences of California Q2 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences shares rise 11.11% premarket after reporting smaller-than-expected Q2 loss and positive trial data. - AInvest
PacBio Narrowed Losses As New Tech And China Deal Paid Off - Finimize
Pacific Biosciences of California Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - sharewise.com
PacBio (NASDAQ:PACB) Delivers Strong Q2 Numbers, Stock Soars - TradingView
Pacific Biosciences Q2 Earnings: Smaller Loss Than Expected - AInvest
PacBio Announces Second Quarter 2025 Financial Results - GlobeNewswire
Pacific Biosciences Q2 Earnings Exceed Expectations with $39.8M Revenue and -$0.13 Non-GAAP EPS - AInvest
PacBio to Present at Upcoming Investor Conferences - 富途牛牛
PacBio to Present at Upcoming Investor Conferences in August and September 2025 - Quiver Quantitative
PacBio (PACB) Q2 Earnings Report Preview: What To Look For - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Will Pacific Biosciences of California Inc. Reverse From Oversold ConditionsChart Driven High Reward Trading Setup Presented - beatles.ru
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
PacBio and Collaborators Release Landmark Platinum Pedigree Dataset, Enhancing Genomic Variant Accuracy by 34% With AI Integration - Quiver Quantitative
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models - Yahoo Finance
How strong is Pacific Biosciences of California Inc. company’s balance sheetGet expert advice on portfolio optimization - Jammu Links News
When is Pacific Biosciences of California Inc. stock expected to show significant growthOutstanding capital returns - Jammu Links News
What catalysts could drive Pacific Biosciences of California Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
Should I hold or sell Pacific Biosciences of California Inc. stock in 2025Superior risk-adjusted returns - Jammu Links News
How does Pacific Biosciences of California Inc. generate profit in a changing economyAchieve rapid wealth accumulation with smart picks - Jammu Links News
What institutional investors are buying Pacific Biosciences of California Inc. stockUnprecedented profits - Jammu Links News
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):